Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Assets Average (2022 - 2025)

Historic Assets Average for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $339.5 million.

  • Zentalis Pharmaceuticals' Assets Average fell 2795.0% to $339.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.5 million, marking a year-over-year decrease of 2795.0%. This contributed to the annual value of $491.0 million for FY2024, which is 998.84% down from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Assets Average of $339.5 million as of Q3 2025, which was down 2795.0% from $367.9 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Assets Average's 5-year high stood at $603.6 million during Q3 2023, with a 5-year trough of $339.5 million in Q3 2025.
  • For the 4-year period, Zentalis Pharmaceuticals' Assets Average averaged around $494.1 million, with its median value being $519.5 million (2023).
  • In the last 5 years, Zentalis Pharmaceuticals' Assets Average skyrocketed by 1409.84% in 2023 and then crashed by 2987.45% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Assets Average (Quarter) stood at $534.3 million in 2022, then rose by 6.45% to $568.7 million in 2023, then fell by 22.54% to $440.5 million in 2024, then dropped by 22.93% to $339.5 million in 2025.
  • Its Assets Average stands at $339.5 million for Q3 2025, versus $367.9 million for Q2 2025 and $407.2 million for Q1 2025.